Vergent Bioscience Secures $21.5 Million Series B Financing To Advance Clinical Development Of Tumor-Targeted Fluorescent Imaging Agent Vgt-309
PRIVATEOct 04, 2022
Amount Raised
$21.5 Million
Round Type
Series B
MinneapolisBiotechnologyHealth CareTherapeutics
Description
Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, today announced the close of a $21.5 million Series B financing. Vergent will use the funds to advance clinical development of VGT-309, the company’s targeted fluorescent imaging agent that enables surgeons to see previously undetected or difficult-to-find tumors in real-time, ensuring all tumor tissue is removed during open, minimally invasive (MIS) and robotic-assisted surgical procedures.
Who to call at Vergent Bioscience, and when
A new round usually means Vergent Bioscience is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Vergent Bioscience raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Vergent Bioscience, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Vergent Bioscience
Location
5810 W 78TH ST
Minneapolis, Minnesota, United States
About
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors.
Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.
Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vergent Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MinneapolisBiotechnologyHealth CareTherapeutics